Why Axsome Therapeutics Stock Is Trading Higher
Axsome Therapeutics Inc (NASDAQ: AXSM) is trading higher Monday morning after the company announced it will acquire Sunosi from Jazz Therapeutics PLC (NASDAQ: JAZZ).
Axsome Acquires Sleep Disorder Drug From Jazz Pharma, Expanding Its Neuroscience Portfolio
Axsome Therapeutics Inc (NASDAQ: AXSM) has
Axsome Therapeutics To Acquire Sunosi From Jazz Pharmaceuticals For $53M Upfront, Plus Royalties
Under the terms of the agreement, Axsome will receive from Jazz worldwide commercial, development, manufacturing, and intellectual property rights to Sunosi, except for certain Asian markets. Jazz will receive from
SVB Leerink Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $50
SVB Leerink analyst Marc Goodman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $65 to $50.
Axsome Therapeutics: Q4 Earnings Insights
Axsome Therapeutics (NASDAQ:AXSM) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stock Wars: Axsome Therapeutics Vs. Global Blood Therapeutics
Benzinga’s weekly Stock Wars matches up two leaders in a major industry sector with the goal of determining which company is the better investment.
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers
ContraFect (NASDAQ:CFRX) stock moved upwards by 4.9% to $2.76 during Friday's after-market session. The company's market cap stands at $108.5 million.
SVB Leerink Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $65
SVB Leerink analyst Marc Goodman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $75 to $65.
Axsome Therapeutics Q3 EPS $(0.93) Beats $(0.95) Estimate
Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(0.93) per share which beat the analyst consensus estimate of $(0.95) by 2.11 percent. This is a 52.46 percent decrease over losses of $(0.61) per share